A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/16 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2566199
This application refers to microspheres comprising oligonucleotides for treatment of type 1 diabetes, said oligonucleotides comprise between about 30 weight percent and about 100 weight percent of the microspheres, based on the total weight of the microspheres, said microspheres having an average particle size of not greater than about 50 microns. The oligonucleotides are targeted to bind to primary transcripts selected from the group consisting of CD40, CD80 and CD86 primary transcripts, and combinations thereof.
Selon cette invention, des oligonucléotides antisens sont administrés sous forme de microsphères afin d'induire la tolérance de cellules dendritiques, plus spécifiquement dans le modèle de souris non obèse diabétique (NOD). Ces microsphères comprennent des oligonucléotides antisens (AS). L'invention concerne également un procédé consistant à mettre en oeuvre une approche antisens pour empêcher un état de diabète insulino-dépendant dans des souris NOD in vivo et in situ. Les oligonucléotides sont ciblés pour se lier à des transcrits primaires CD40, CD80, CD86 et aux combinaisons de ceux-ci.
Bisker-Leib Vered
Brown Larry R.
Giannoukakis Nick
Lafreniere Deborah
Machen Jennifer
Baxter Healthcare S.a.
Baxter International Inc.
Children's Hospital Of Pittsburgh
Sim & Mcburney
LandOfFree
Oligonucleotide-containing microspheres, their use for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide-containing microspheres, their use for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide-containing microspheres, their use for the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1593737